Beginner's Mind

Beginner's Mind

Download on the App Store

All Beginner's Mind episodes

  • #61: Bettina Resl, Sascha Berger,Tilmann Buerckstuemmer, Thomas Moser, Kimberly Cornfield - This was 2021 - A Year in Review Part 2/7

    Part 2 of the Year in Review Recording.

     1 hour 15 minutes of exciting conversations with speakers from previous podcast episodes and business partners of the hosts.

     What was hot in 2021, and what do our speakers expect for 2022?

    In this episode, we talk about

    • Health Literacy and the Healthcare System
    • Venture Capital in 2021
    • Digitalization in Drug Development
    • The Golden Age of Biotech
    • Home Office – How Work-Life will Look like in the Post Pandemic World

    I hope you enjoy the conversation the same way I did.

    Who are the Experts in this episode:

    • Bettina Resl
    • Sascha Berger
    • Tilmann Buerckstuemmer
    • Thomas Moser
    • Kimberly Cornfield

    Video to the Episode: https://youtu.be/HL-z1c_1XaU

    Timestamps:
    (02:00) Bettina Resl - Christmas Greetings
    (03:11) Review of 2021  - Challenges for the Healthcare System in 2021 Beyond Covid 19
    (06:32) Healthy Habits are the First Step to Longevity
    (07:32) How Do Pharma Reach Patients?
    (09:12) The Importance of Health Literacy – Concept and Strategies to Improve Health Literacy for the People
    (16:56) What Happens to Home Office in a Post-Pandemic World
    (20:00) Sascha Berger – Recap of 2021
    (21:45) Significant closings in the Life Science VC world during the pandemic
    (22:57) Lasting Effects of the Capital Flow Towards Life Science
    (25:20) Will the Development Speed in the Pharma Industry in 2020/21 be Lasting?
    (29:17) The Digital Revolution – Does it Affect the Dealflow of Life Science VCs?
    (31:55) Outlook for 2022
    (32:25) Conference Plans for 2022
    (33:29) Thomas Moser and Tilmann Buerckstuemmer – Aelian Biotechnology
    (35:33) Aelian Biotechnology – This was 2021
    (36:00) Bit.BioDiscovery – Finding New Cell Types – The Holy Grail of Biology
    (37:14) Outsourcing Trend for Pharma and Biotech Companies
    (38:00) Trend to Digitalisation
    (39:38) Data – Is it More Signal or More Noise?
    (41:39) CRISPR - Trends
    (42:40) The Golden Age of Biotech
    (44:18) What is the Big Goal for The Holy Grail of Biology?
    (46:34) Golden Age of Biotech or Bubble Territory?
    (47:39) Increasing Health and Financial Literacy for the Common Good of Society
    (48:18) Data Security in Gene Editing
    (49:42) Paradigm Shift in Data Storage
    (54:38) Outlook for 2022 – Aelian Biotech
    (57:00) Astrid Wollard and Matthias Tarasiewicz – Recap of 2021
    (58:51) Talent Shortage
    (01:01:15) Web 2.0 vs. Web 3.0
    (01:01:55) Use-Cases in Web 3.0 Beyond Token
    (01:02:00) Kimberly Cornfield - Intro
    (01:02:30) Research Activities at the UCL in Web 3.0 and Beyond
    (01:04:00) European Research & Innovation at the UCL
    (01:05:00) Effects of the Brexit on European Collaboration with British Universities
    (01:07:00) How Did Collaborations between Universities Change With the Pandemic?
    (01:08:29) Outlook for 2022 – Focused Research Areas
    (01:10:20) Big Trends in Research in 2021
    (01:11:00) Artificial Intelligence, Democracy, and Education
    (01:11:48) Astrid Woollard – Potential of Artificial Intelligence
    (01:13:00) Matthias Tarasiewicz – AI and Machine Learning in this decade
    (01:15:32) Kimberly Cornfield – Horizon Europe 2022

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 20 min
  • #60: Astrid Woollard, Dusica Lukac, Matthias Tarasiewicz, Irénée Robin - This was 2021 - A Year in Review Part 1/7

    This is Part 1 of the 7,5 hours conversations marathon before Christmas with speakers from previous podcast episodes and business partners of the host and co-host of the Podcast.

    In this episode, we talk about

    • Covid19 
    • Cryptocurrencies
    • Cybersecurity and
    • Merger & Acquisition

    I hope you enjoy the conversation the same way as I did.

    Who are the Experts in this episode:

    • Astrid Woollard
    • Dusica Lukac
    • Matthias Tarasiewicz
    • Irénée Robin

    Video to the episode: https://youtu.be/s3R93Dmoy6U

    Timestamps:
    (00:00) Opening

    (03:15) Astrid Woollard – Foundation of SMAPE Capital and Blockchain Technology

    (04:31) How to Manage 80-100 Opportunities per month

    (05:39) Focus of SMAPE Capital

    (08:00) What is DAO?

    (08:35) Selling of one of the First Copies of the US Constitution for 42.5 Million Dollar

    (10:30) Potential of DAO in Fundraising for Startups

    (11:30) Astrid’s Outlook for 2022

    (13:00) Price Predictions for BTC and ETH for 2022

    (14:15) Dusica Lukac”The Transaction Diva”  – M&A in 2021

    (20:30) M&A in Crypto in 2022

    (22:30) Great Transactions in 2022

    (24:30) Outlook for 2022

    (26:00) Which Sector will Dominate 2022?

    (28:15) Matthias Tarasiewicz – Covid 19 and Cybersecurity

    (36:30) How to Raise Awareness for the Need of Cybersecurity?

    (40:00) Messenger Services like Whatsapp, Telegram or Signal and Cybersecurity

    (42:15) How Billionaire Entrepreneurs Influence the Public Opinion about Tech

    (44:15) Irénée Robin – Vaccines and Therapeutics against SARS CoV 2

    (46:45) Expectations on the development of travel restrictions

    (47:30) How Did the Drug Development and Vaccine Space evolve since September 2020?

    (48:30) The 3 Legs of a Pandemic Response

    (55:15) The Success of Pharma in the Pandemic Response

    (58:30) Difference Between Tamiflu and c Antiviral Drugs for the SARS CoV 2 Response

    (01:03:40) Matthias Tarasiewicz - Supply Chain Issues as a Result of the Pandemic – Hardware, Chips, Drugs

    (01:08:40) Supply Chains in Pharma in 2021 

    (01:11:45) Open Sourcing Medical Devices

    (01:13:00) Why Did the Development of Therapeutics Take Longer Than Vaccines?

    Podcast Links:
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    Podcast Community: https://lsg2g.substack.com/
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV
    Podcast Website: https://www.lifescienceget2gether.com/





    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 16 min
  • #59: Sascha Berger - TVM Capital - A Perspective on The Life-Science-Eco-System in the US and Europe

    In this episode, I am having a conversation with Sascha Berger, Partner at TVM Capital.

    Dr. Sascha Berger is a Partner at TVM Capital, based in Munich, Germany. TVM Capital is one of the pioneer transatlantic Life Science Venture Capital funds with Europe and North America teams. Sascha joined TVM Capital in 2016, helped raise the current $480M fund, and works closely with entrepreneurs and founders to advance promising pharmaceutical assets, MedTech, diagnostic, and digital health technologies to the following value inflection points. Sascha is a passionate VC, a Boston Consulting Group alumnus, and has an academic chemistry and finance background.

    TVM Capital is a dedicated life science venture capital firm with Europe and North America teams. Since its inception, TVM Capital has invested in entrepreneurial venture-backed companies. Over several fund generations, TVM Capital’s investment strategy has included a multi-stage investment approach spanning discovery to market-ready companies as well as profitable companies searching for growth capital. The investment focus has always been broad and includes investments in therapeutics, technology platforms, MedTech, and diagnostics.

    In this episode, we talk about

    • How the Life Science Eco-Systems evolved in the US and Europe
    • TVM Capitals Investment Approach
    • How to reach out to VCs
    • And much more...

    I hope you enjoy the conversation the same way as I did.

    Who is the Expert in the show?

    • Sascha Berger
    • TVM Capital

    Shownotes: https://lsg2g.substack.com/p/59-a-perspective-on-the-life-science

    Video to the Episode: https://youtu.be/pQxjm-uv61g

    Timestamps:
    00:00) Intro
    (02:30) The History of TVM Capital
    (05:45) The Development of Life Science Eco-Systems in Europe and North America
    (10:35) What Possibilities Do Founders Have Today to Move their Companies Forward – From the Investors Perspective
    (13:45) Long Term Investment Models in the Life Science Industry
    (17:40) Cultural Differences between North America and Europe
    (23:50) How to Create Companies That Become Targets for VCs
    (27:10) How Important is the Growth Potential of a Company for TVM?
    (29:05) How Much Time do VC Processes Take?
    (33:35) When is the Right Time to Reach out to VCs?

    Podcast Links:
    Podcast Website: https://www.lifescienceget2gether.com/
    Podcast Community: https://lsg2g.substack.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    39 min
  • #58: Bettina Resl - Trends in the Pharma Industry in the 21st Century

    In this episode, I am having a conversation with Bettina Resl, Public Affairs Head Europe Consumer Healthcare at Sanofi.

    Bettina Resl joined Sanofi Austria in May 2017 as Country Head Public Affairs & Patient Advocacy.
    From April 2020 to June 2021 she was also responsible for corporate communications and finally took over the position of Public Affairs Head Europe Consumer Healthcare at Sanofi on July 1, 2021.

    Sanofi is dedicated to supporting people through their health challenges. Sanofi is a global biopharmaceutical company focused on human health, preventing illness with vaccines, provide innovative treatments to fight pain and ease suffering. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

    In this episode, we talk about

    • Collaboration in the Pharmaceutical Industry
    • The Pharma Value Chain
    • The Role of Patents 
    • And much more….

     I hope you enjoy the conversation the same way I did.

    Who is the Expert in the show?

    • Bettina Resl
    • Sanofi

    Shownotes: https://lsg2g.substack.com/p/58-trends-in-the-pharma-industry

    Video to the Episode: https://youtu.be/Jadsxf9DL0w

    Timestamps:
    (00:00) Introduction
    (03:40) Introduction Bettina Resl
    (04:05) What are the Duties of a Public Affairs Head Europe Consumer Healthcare at Sanofi
    (10:50) What Best Practices from the Development of Vaccines and Therapeutics against Sars Cov 2 can be conserved in the Pharma Industry?
    (14:50) Will the collaborative spirit of 2020/21 remain in the pharma industry?
    (17:33) Personalized Medicine
    (22:32) Early Stage Development Quo Vadis?
    (26:22) The Future Role of Big Data in Pharma and the Healthcare System
    (31:57) Are we at the Dawn of a New Golden Age of Biotech?
    (38:38) What is the Future of Early-Stage Development in Life Science in Europe?
    (42:00) Success Rates in Early-Stage-Development in Pharma
    (44:11) What is the Future of mRNA Technology?
    (47:49) Longevity Research – Quo Vadis?
    (53:25) The Future of Digitally Enhanced Healthcare Systems
    Entry
    (59:10) The Future of Diagnostics
    (01:03:56) Mental Health in Pharma
    (01:08:28) The Future of Patents in the light of a fair global distribution of vaccines and therapies
    (01:14:19) What are the 3 biggest bottlenecks in the pharmaceutical industry?
    (01:18:00) Final Question: What is the most important event or innovation in the Pharma Industry with the highest impact in the coming 10 years?

    Podcast Links:
    Podcast Website: https://www.lifescienceget2gether.com/
    Podcast Community: https://lsg2g.substack.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 22 min
  • #57: Jaromír Zahrádka - Bridging Science and Business in the European Life Science Eco-System

    In this episode, I have a conversation with Jaromir Zahradka and we will talk about early-stage investments in DeepTech Life Science companies. 

    He has 5+ years of C-level experience and has been engaged in 8 Biotech spin-offs.  He built a unique network within CE institutions and TTOs and has deep scientific and licensing market expertise with over 20 licensing deals worth more than USD 500m. 

    Jaromír was a co-founder of i&i Prague, a biotechnology incubator.

     In this episode, we will  talk about

    •  Early-stage investments in a deep tech company
    • The complexity of spinning out technology from research organizations and
    • The venture capital situation in Europe
    • and much more

     I hope you enjoy the conversation the same way I did.

    Who is the Expert in the show?

    • Jaromír Zahrádka
    • i&i Prague
    • i&i Biotech Fund
    • IOCB Tech
    • IOCB Prague

    Shownotes: https://lsg2g.substack.com/p/57-bridging-science-and-business

    Video to the Episode: https://youtu.be/HJ_81X-yqz0

    Timestamps:
    (00:00) Intro

    (01:43) Start of The Episode

    (02:55) A New Fund In Town – I&I Biotech Fund

    (04:40) Investment Area of i&I Biotech Fund

    (06:15) How is it to found a life science fund?

    (09:12) What are the challenges in raising a life science fund?

    (13:25) A Fund is Teamwork

    (16:06) The Life Science R&D Eco-System in Prague

    (28:45) Top Level Expertise at the IOCB in Prague

    (31:09) The Role of Tech Transfer Offices in the Value Chain

    (39:31) How to Turn Science Into Business

    (55:20) The Role of Capital in Deep Tech Life Science

    (01:02:50) The Development of Talent – A Key Success Factor

    (01:06:30) The perspective of Long Term Investment Funds

    (01:12:15) How Can the European Deep Tech Investment Eco-System Evolve Better?

    (01:19:00) Cross-Sector and International Collaborations in Europe

    (01:22:30) What is the First Step Towards Turning Science into Products and Businesses?

    Podcast Links:
    Podcast Website: https://www.lifescienceget2gether.com/
    Podcast Community: https://lsg2g.substack.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 28 min
  • #56: Ole Dammann - How to Do Clinical Research in Europe

    In today’s episode, we explore Clinical Development with Ole Dammann, the owner of KFGN, a group of 6 clinical trial sites in Germany, and after joining Pratia, several sites in Eastern Europe.

    Ole Dammann is one of the best experts in clinical trial management in the LSG2G Community. Ole is currently working on the digitization of clinical research and the development of new business models.

    In this episode, we will talk about

    • Business Models in the Life Science Industry
    • Clinical Trial Management
    • Changes in the Business World in the last three decades 
    • Digital Health Revolution and
    • Much more

    Who is the Expert in the show?

    • Ole Dammann 
    • CEO of KFGN Group 

    Shownotes
    https://lsg2g.substack.com/p/56-how-to-do-clinical-research-in

    Video to the Episode

    Timestamps:
    (00:00) Intro
    (02:30) Life in Germany in October 2021
    (05:50) Foundation of KFGN Group in the 90s
    (07:25) Extending the Clinical Network to Eastern Europe
    (09:10) How to Start a Collaboration During the Pandemic
    (12:15) How were Clinical Trials Organized in the 90s compared to today?
    (17:00) Clinical Trials and Big Data
    (19:20) The European Funding Gap for Startup and Scaleup Companies
    (23:20) Business Models for Clinical Trial Management in the 90s
    (28:35) Clinical Trials in Separate Sites – Offering New Solutions to Patients
    (30:40) The Effects of Personalized Medicine on the Complexity of Clinical Trial Management
    (35:20) Rare Diseases and the Challenges For Clinical Trial Management
    (38:30) Personalized Clinical Trial Management – Bring the Sites to the Patients
    (41:20) Effects of Wearable Technology on Clinical Trials
    (44:15) Wearable Technology and Data Collection for Clinical Trials
    (47:45) Making Science and Data Understandable and Relatable
    (50:00) Digital Therapeutics
    (52:50) Current State of Digital Therapeutics
    (53:40) Longevity and Clinical Trials
    (55:40) What Makes The Eco-System Around the Stanford University so Unique?
    (59:15) What is the True Sense of Business?
    (01:01:00) Tesla, Apple, Alphabet, Facebook, Stanford University, Palo Alto Networks – Shaping the Entrepreneurial Bay Area Mindset
    (01:03:15) Advantages of the European Mindset
    (01:05:00) What is the Right Point in Time for Early-Stage Companies to Involve Clinical Experts?


    Podcast Links:

    Podcast Website: https://www.lifescienceget2gether.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 16 min
  • #55: Peter Llewellyn-Davies - The Future of Life Science Entrepreneurship and Investment in Europe

    In this conversation, I will talk with Peter Llewellyn-Davies, CEO of Apeiron and President of Biotech Austria about the Future of Life Science Entrepreneurship and Investment in Europe.

    Topics we discuss in the show:

    • The Development of the Life Science Eco-System in Europe
    • How Family Offices Support Life Science Companies in Europe
    • How to Translate Science into Business
    • Does Europe Have a Culture of Success?
    • And much more...


    Who is the Expert in the show?

    • Peter Llewellyn-Davies 
    • CEO of Apeiron Biologics 
    • President of Biotech Austria 


    Shownotes:

    Video to the Episode

    Timestamps:
    (00:00) Opening
    (01:25) How did the Life Science Ecosystem Evolve?
    (03:22) The Biontech Success Story
    (04:10) How Did The Private and Publice Sector Evolve in Europe Since 2006?
    (05:49) What is Biotech Austria’s Mission?
    (07:00) How Many Members Does Biotech Austria Have in 2021?
    (09:10) Biotech Success Stories From Austria
    (11:40) Vienna, Austria, Local Life-Science-Eco-Systems and Biontech’s Success
    (13:45) Why is it a Great Decision to Start a Life Science Company in Austria?
    (16:26) Where Do Scientists Get Follow On Funding From?
    (18:30) How Helpful is the New European Investment Regulation for Foreign Investors?
    (21:00) Fundraising Challenges for Life Science Companies
    (24:00) Why Life Science Investments Are Attractive
    (25:50) How to Get in Touch With Biotech Austria

    Podcast Links:
    Podcast Website: https://www.lifescienceget2gether.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    30 min
  • #54: Oliver Mavher and Michael Deichsel - Crypto Trading and Taxes - The Past, The Present, and The Future

    In this conversation, I will talk with Oliver Mavher and Michael Deichsel about Crypto Trading and taxes.

    Topics we discuss in the show:

    The questions that I consider relevant for everybody owning digital assets:

    • What if someone gets paid in Bitcoin or other Cryptocurrencies? Is that a taxable event?
    • What if someone invests in those novel digital assets and they gain in value?
    • Does the location of the wallet or crypto exchange make any difference for taxation? Which tax law is applicable?
    • What about European ETFs and their offshore counterparts that replicate the price of digital assets?
    • What about investments in companies that invest in digital assets?
    • Are there differences between retail investors, investment funds, and other institutional investors?
    • And many more questions similar to the above


    Who are the Tax Experts in this Episode?

    I am delighted to welcome

    • Oliver Mavher, KPMG and
    • Michael Deichsel, KPMG

    to find answers to a multiverse of questions around crypto investments and taxes.

    Shownotes:

    • Link


    Video

    • Link


    Timestamps:

    (00:00) Opening What are the Real Life Tax Consequences of Trading with Cryptocurrencies?

    (02:47) Opening Oliver Mavher – Support for Digital Companies in Tax Matters

    (08:45) What are Security Token Offerings?

    (11:00) Opening Michael Deichsel – Crypto and Taxes

    (16:10) What is the Tokenization of the Economy?

    (18:15) Smart Contracts

    (24:15) What are Digital Assets in Terms of Tax Laws?

    (27:00) Bitcoin as Legal Tender in El Salvador?

    (29:07) Banking the Unbanked.

    (30:55) Cryptocurrencies and the Environment

    (34:13) What are crypto assets?

    (37:00) What are NFTs?

    (39:00) NFT and Taxations in Austria

    (45:30) Changes in Tax Laws in Austria

    (49:05) Taxable Events when BTC is used for salaries

    (54:15) Using Cryptocurrencies for everyday purchases – what are the taxable events?

    (56:45) Taxable events when trading cryptocurrencies outside Austria – A case for double taxation treaties?

    (01:00:00) Different Cases for Taxation and their Consequences

    (01:03:00) Taxation for Companies when holding Digital Assets

    (01:07:00) Expected changes to the tax laws

    (01:09:00) The difference in Taxation between Crypto Currencies and Digital Assets

    (01:13:00) Where to get advice for Crypto Taxation?

    Podcast Links:
    Podcast Website: https://www.lifescienceget2gether.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 19 min
  • #53: Alexander Schwartz and Ingrid Kelly Spillman - The Future of Early-Stage Deep Tech Investments in Europe

    In this conversation, we will talk about the future of the Early-Stage Ecosystem in Europe.

    Speaker in the Episode:

    Alexander Schwartz joined IST cube in 2018 as a Partner. He has more than 15 years of experience in management consulting, eight of which with McKinsey & Company.

    Ingrid Kelly Spillman joined the IST Tech Transfer team in October 2018. Ingrid worked as a patent attorney in and for the pharma industry for more than a decade.

    IST cube focuses on startups with a strong background in science and technology, such as academic spin-offs or young deep tech companies. 

    Topics we discuss in the show:

    In this conversation, we discuss:

    • Ecosystems
    • Early-Stage Investments
    • VC Investment Stories
    • From Science to Business
    • The IST Ecosystem
    • and much more…

    Shownotes:

    • Link

    Video

    • Link

    Timestamps:
    (00:00) Introduction

    (02:50) Introduction Alexander 

    (04:12) Introduction Ingrid 

    (06:05) How are IST, Twist, and IST Cube linked?

    (09:21) The Success Story of IST – from Greenfield Operations to Top 3 in 15 years

    (13:20) IST Cube’s Role in the Early-StageCommunity

    (16:45) The People behind IST Cube

    (19:00) Investment Focus of IST Cube

    (21:50) What is the attractive opportunity in early-stage investments?

    (26:00) When is the right time to reach out to VCs?

    (29:30) How Academic and Business Mindset work Together in Early-Stage Development

    (34:45) The Attitude for Fundraising Companies

    (38:20) What is the right timing for creating a spin-out company?

    (43:14) What deal structures are possible for early-stage companies?

    (48:25) Entrepreneurial Expertise in the European Eco-System

    (58:50) Startup Business Models in the Early-Stage Investment Eco-System

    (01:03:00) How Investors and Start-Ups Work Together to bring positive change to the World

    (01:06:00) The IST Cube Eco-System in 2021 – Build Around Collaboration and Open Innovation

    (01:09:15) How The Innovation Eco-System in Austria Collaborates to Support Companies to go from Zero to One

    (01:12:00) How IST Cube Helps Scientists Making the Transition from Academia to Business

    (01:17:00)Ideas for the European Eco-System

    (01:20:10) Failure Culture in Europe

    (01:23:30) Exit Strategies for Founders and Investors

    (01:28:35) Four Attributes Startups Should Have to Fit into VC Models.

    (01:32:40) What is the essential first step in the creation of a new company?

    Podcast Links:
    Podcast Website: https://www.lifescienceget2gether.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 37 min
  • #52: Caroline Heil - Driving the Future of Meat

    The industry gains complexity, and I am happy that a speaker from the LSG2G community has dedicated time to speak about the Future of the Food Industry.

    Speaker in the Episode: Dr. Caroline E. Heil

    Since Jul. 1, 2021, Caroline has been CEO of The New Meat Company AG, a young stock-listed, purpose-driven impact investment company in Berlin focusing on alternative proteins. 

    Caroline is intrigued by the idea of revolutionizing the food industry, especially everything animal production-related, in an environmentally friendly, healthy, and sustainable way that will allow us to feed +10 billion people in the future.


    Before joining TNMC, Caroline worked for EY as a lawyer and part of the global EY Agribusiness Team. 

    The New Meat Co.

    The firm invests in game-changing companies and founders that disrupt the status quo of the meat industry to create nutritious, tasty, and sustainable meat alternatives that are good for everyone – animals, humans, and our planet.

    Topics we discuss in the show:

    In this conversation, we discuss the Future Of the Food Industry and talk about topics like: 

    • Alternative proteins
    • Nutraceuticals
    • Functional food
    • Reworking the supply chain
    • 3d printing of food
    • Personalized nutrition
    • And much more…

    Follow Caroline E. Heil and The New Meat Co.:

    • Caroline Heil on Linkedin
    • The New Meat Co on Linkedin

    Shownotes:
    Article on Substack

    Timestamps:

    00:00 Opening

    02:25 The New Meat Company – New Trends in the Food Industry

    05:06 The Environmental Footprint of the Foot Industry in 2021

    08:08 Sustainability of the Food Industry

    10:14 Introduction Caroline Heil

    14:36 Innovation in the Meat Industry

    19:10 Sustainability of Analog Meat

    22:00 The Health Impact of Nutrition

    28:35 Solving the Global Distribution of Food with Modern Technology?

    34:38 The Hellofresh Case – High-Quality Food at Low Prices

    39:57 Consumer Trends in the Food Industry

    42:23 Insects as Protein Source?

    46:20 Lab-Grown Meat

    57:45 How Industry and StartUps Can Evolve Together

    01:00:00 Mission Statement of The New Meat Company

    01:03:20 What Invention Will Have the Biggest Impact on The Food Industry in This Decade?

    01:06:50 3D Printing of Food

    01:11:20 Longevity and the Food Industry

    Podcast Links:
    Podcast Website: https://www.lifescienceget2gether.com/
    Community Partner: https://linktr.ee/lsg2g
    Christian Soschner: https://linktr.ee/soschner
    LSG2G Twitter: https://twitter.com/LGet2gether
    LSG2G Linkedin: https://www.linkedin.com/company/life-science-get2gether
    Podcast Episodes: https://pod.link/1493847125
    Episodes on YouTube:  https://www.youtube.com/playlist?list=PLlZfrwd6iXrQ3LIANISUpP22seS2CsCEV

    Send us Fan Mail

    Support the show

    Join the Podcast Newsletter: Link

    Your Next Move: Link

    1 hr 16 min